Immune Checkpoint Inhibitor-Associated Optic Neuritis

Jasmine H Francis; Korey Jaben; Bianca D Santomasso; Julia Canestraro; David H Abramson; Paul B Chapman; Meghan Berkenstock; Mary E Aronow

doi:10.1016/j.ophtha.2020.05.003

Immune Checkpoint Inhibitor-Associated Optic Neuritis

Ophthalmology. 2020 Nov;127(11):1585-1589. doi: 10.1016/j.ophtha.2020.05.003. Epub 2020 May 8.

Authors

Jasmine H Francis¹, Korey Jaben², Bianca D Santomasso³, Julia Canestraro⁴, David H Abramson², Paul B Chapman⁵, Meghan Berkenstock⁶, Mary E Aronow⁷

Affiliations

¹ Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Ophthalmology, Weill Cornell Medical Center, New York, New York. Electronic address: francij1@mskcc.org.
² Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Ophthalmology, Weill Cornell Medical Center, New York, New York.
³ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Neurology, Weill Cornell Medical Center, New York, New York.
⁴ Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, New York.
⁶ Ocular Immunology Division, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.
⁷ Retina Service, Massachusetts Eye and Ear Harvard Medical School, Boston, Massachusetts.

Abstract

The three classes of immune checkpoint inhibitors can be associated with optic neuritis, which typically presents with bilateral, painless visual decline. Visual function stabilized with drug cessation and systemic steroids.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aged
Female
Humans
Immune Checkpoint Inhibitors / adverse effects*
Male
Middle Aged
Multiple Sclerosis / drug therapy*
Optic Neuritis / chemically induced*
Optic Neuritis / immunology

Substances

Immune Checkpoint Inhibitors

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States